Sandoz (SDZ) Sandoz Strategic Review 2024 summary

Strategic and Financial Overview

• Leadership reaffirmed commitment to global generics and biosimilars leadership, serving over 800 million patient treatments annually and targeting net-zero emissions by 2050.

• The company operates in a $200 billion off-patent medicines market, with biosimilars driving recent 7% sales growth and contributing to a quarter of revenues.

• Generics represent 77% of total sales, with scale across major therapeutic areas and strong cash flow to support innovation.

• Margin expansion targets (from 18% in 2023 to 24–26% by 2028) will be achieved through volume/mix, operational improvements, and organizational efficiency.

• Transformation and separation programs are underway, with significant investments in IT, manufacturing, and organizational streamlining to support future growth.

Regional Business and Market Positioning

• Europe remains the core market, with leadership in both generics and biosimilars, leveraging strong local relationships and infrastructure.

• North America is a key growth driver, expected to deliver 50% of mid-term topline growth, with recent biosimilar launches and a renewed generics pipeline.

• US business outpaces the biosimilars market, with Hyrimoz as the #1 adalimumab biosimilar and broad payer coverage.

• Canada and Brazil serve as early markets for GLP-1 launches, providing insights for future expansion into larger markets.

• International business is growing via direct presence in select markets and targeted M&A.

Pipeline, Launches, and Innovation

• Over 70 generics and 7 biosimilars targeted for launch by 2028, addressing a combined LoE value of approximately $130bn.

• Recent and upcoming launches include Hyrimoz, Tyruko, Pyzchiva, Wyost/Jubbonti, and Enzeevu, with strong initial uptake and market share gains.

• The GLP-1 segment is a major long-term focus, with phased market entry and investments in multi-use injectable capacity.

• Strategic partnerships and investments in manufacturing, including a new biosimilars site in Slovenia and adoption of continuous manufacturing technology, enhance capacity and efficiency.

• Future pipeline includes antibody-drug conjugates (ADCs) and oligonucleotides, with a disciplined approach to asset selection and external partnerships.